Expression of gp185(HER-2) in human cutaneous melanoma: Implications for experimental immunotherapeutics

P. G. Natali, M. R. Nicotra, G. Digiesi, R. Cavaliere, A. Bigotti, D. Trizio, O. Segatto

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Over-expression of the HER-2 oncogene correlates with poor prognosis in breast and ovarian carcinomas. Using a sensitive immunohistochemical assay, we have detected low levels of gp185(HER-2) in intradermal nevi (78%) and in primary (75%) and metastatic melanomas (58%). The HER-2 gene product expressed by cultured melanoma cells had the expected molecular weight, but no levels of tyrosine phosphorylation could be detected. Consistently, we were unable to inhibit in vitro growth of melanoma cells with an anti- gp185(HER-2) MAb, in conditions in which the growth of SKBr-3 breast- carcinoma cells was severely impaired. However, immunotoxins to gp185(HER-2) were able to kill gp185(HER-2)-positive melanoma cells. These data indicate that low levels of gp185(HER-2) are expressed by the melanocyte lineage, with no correlation with transformation or tumor progression. Nevertheless, gp185(HER-2) appears a suitable target for immunotherapy of cutaneous melanoma.

Original languageEnglish
Pages (from-to)341-346
Number of pages6
JournalInternational Journal of Cancer
Volume56
Issue number3
Publication statusPublished - 1994

Fingerprint

Experimental Melanomas
Melanoma
Skin
Intradermal Nevus
Breast Neoplasms
erbB-2 Genes
Immunotoxins
Melanocytes
Growth
Oncogenes
Immunotherapy
Tyrosine
Cultured Cells
Molecular Weight
Phosphorylation
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Natali, P. G., Nicotra, M. R., Digiesi, G., Cavaliere, R., Bigotti, A., Trizio, D., & Segatto, O. (1994). Expression of gp185(HER-2) in human cutaneous melanoma: Implications for experimental immunotherapeutics. International Journal of Cancer, 56(3), 341-346.

Expression of gp185(HER-2) in human cutaneous melanoma : Implications for experimental immunotherapeutics. / Natali, P. G.; Nicotra, M. R.; Digiesi, G.; Cavaliere, R.; Bigotti, A.; Trizio, D.; Segatto, O.

In: International Journal of Cancer, Vol. 56, No. 3, 1994, p. 341-346.

Research output: Contribution to journalArticle

Natali, PG, Nicotra, MR, Digiesi, G, Cavaliere, R, Bigotti, A, Trizio, D & Segatto, O 1994, 'Expression of gp185(HER-2) in human cutaneous melanoma: Implications for experimental immunotherapeutics', International Journal of Cancer, vol. 56, no. 3, pp. 341-346.
Natali PG, Nicotra MR, Digiesi G, Cavaliere R, Bigotti A, Trizio D et al. Expression of gp185(HER-2) in human cutaneous melanoma: Implications for experimental immunotherapeutics. International Journal of Cancer. 1994;56(3):341-346.
Natali, P. G. ; Nicotra, M. R. ; Digiesi, G. ; Cavaliere, R. ; Bigotti, A. ; Trizio, D. ; Segatto, O. / Expression of gp185(HER-2) in human cutaneous melanoma : Implications for experimental immunotherapeutics. In: International Journal of Cancer. 1994 ; Vol. 56, No. 3. pp. 341-346.
@article{c7f27adf474449a8b5d055ed4fc6e06a,
title = "Expression of gp185(HER-2) in human cutaneous melanoma: Implications for experimental immunotherapeutics",
abstract = "Over-expression of the HER-2 oncogene correlates with poor prognosis in breast and ovarian carcinomas. Using a sensitive immunohistochemical assay, we have detected low levels of gp185(HER-2) in intradermal nevi (78{\%}) and in primary (75{\%}) and metastatic melanomas (58{\%}). The HER-2 gene product expressed by cultured melanoma cells had the expected molecular weight, but no levels of tyrosine phosphorylation could be detected. Consistently, we were unable to inhibit in vitro growth of melanoma cells with an anti- gp185(HER-2) MAb, in conditions in which the growth of SKBr-3 breast- carcinoma cells was severely impaired. However, immunotoxins to gp185(HER-2) were able to kill gp185(HER-2)-positive melanoma cells. These data indicate that low levels of gp185(HER-2) are expressed by the melanocyte lineage, with no correlation with transformation or tumor progression. Nevertheless, gp185(HER-2) appears a suitable target for immunotherapy of cutaneous melanoma.",
author = "Natali, {P. G.} and Nicotra, {M. R.} and G. Digiesi and R. Cavaliere and A. Bigotti and D. Trizio and O. Segatto",
year = "1994",
language = "English",
volume = "56",
pages = "341--346",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Expression of gp185(HER-2) in human cutaneous melanoma

T2 - Implications for experimental immunotherapeutics

AU - Natali, P. G.

AU - Nicotra, M. R.

AU - Digiesi, G.

AU - Cavaliere, R.

AU - Bigotti, A.

AU - Trizio, D.

AU - Segatto, O.

PY - 1994

Y1 - 1994

N2 - Over-expression of the HER-2 oncogene correlates with poor prognosis in breast and ovarian carcinomas. Using a sensitive immunohistochemical assay, we have detected low levels of gp185(HER-2) in intradermal nevi (78%) and in primary (75%) and metastatic melanomas (58%). The HER-2 gene product expressed by cultured melanoma cells had the expected molecular weight, but no levels of tyrosine phosphorylation could be detected. Consistently, we were unable to inhibit in vitro growth of melanoma cells with an anti- gp185(HER-2) MAb, in conditions in which the growth of SKBr-3 breast- carcinoma cells was severely impaired. However, immunotoxins to gp185(HER-2) were able to kill gp185(HER-2)-positive melanoma cells. These data indicate that low levels of gp185(HER-2) are expressed by the melanocyte lineage, with no correlation with transformation or tumor progression. Nevertheless, gp185(HER-2) appears a suitable target for immunotherapy of cutaneous melanoma.

AB - Over-expression of the HER-2 oncogene correlates with poor prognosis in breast and ovarian carcinomas. Using a sensitive immunohistochemical assay, we have detected low levels of gp185(HER-2) in intradermal nevi (78%) and in primary (75%) and metastatic melanomas (58%). The HER-2 gene product expressed by cultured melanoma cells had the expected molecular weight, but no levels of tyrosine phosphorylation could be detected. Consistently, we were unable to inhibit in vitro growth of melanoma cells with an anti- gp185(HER-2) MAb, in conditions in which the growth of SKBr-3 breast- carcinoma cells was severely impaired. However, immunotoxins to gp185(HER-2) were able to kill gp185(HER-2)-positive melanoma cells. These data indicate that low levels of gp185(HER-2) are expressed by the melanocyte lineage, with no correlation with transformation or tumor progression. Nevertheless, gp185(HER-2) appears a suitable target for immunotherapy of cutaneous melanoma.

UR - http://www.scopus.com/inward/record.url?scp=0028179151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028179151&partnerID=8YFLogxK

M3 - Article

C2 - 7906252

AN - SCOPUS:0028179151

VL - 56

SP - 341

EP - 346

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -